FMS

Family Medicine Specialists Selects Cardio Diagnostics’ Epigenetic-Genetic Tests for Assessing Heart Attack Risk for its BlueCross BlueShield Patients

Retrieved on: 
Tuesday, November 7, 2023
Technology, Biotechnology, Health, Biometrics, Other Health, Artificial Intelligence, Practice Management, Software, General Health, Genetics, Health Technology, Health Insurance, Data Management, Cardiology, Cardio, Splenic infarction, HMO, Obesity, Bangladesh Technical Education Board, Conditional sentence, Diabetes, Organization, Entrepreneurship, Milken Institute, Death, CDC, Risk, PPO, Hypertension, Blue Cross Blue Shield Association, Moyamoya disease, Patient, FMS, CHD, Cardiovascular disease, Heart failure, Medical device, Pharmaceutical industry, Medicaid

The "Heart Attack Prevention" initiative will leverage Cardio Diagnostics' advanced and highly sensitive blood-based epigenetic-genetic tests to risk stratify FMS’ patient population.

Key Points: 
  • The "Heart Attack Prevention" initiative will leverage Cardio Diagnostics' advanced and highly sensitive blood-based epigenetic-genetic tests to risk stratify FMS’ patient population.
  • According to the CDC, nearly 50% of Americans have at least one major cardiovascular risk such as diabetes, obesity, or hypertension.
  • FMS is implementing Cardio Diagnostics’ heart attack risk assessment test, Epi+Gen CHD, in at least 1,200 patients with CHD risk factors with BlueCross BlueShield Medicare, Medicaid, HMO and PPO health plans.
  • This initiative will demonstrate the practical and cost-effective benefits of early heart attack risk detection and intervention.

Biomea Fusion Announces Two Poster Presentations at Upcoming ASH Annual Meeting 2023

Retrieved on: 
Thursday, November 2, 2023
Trae tha Truth, ECOG, Vomiting, CYP3A4, WT, Abstract, NPM1, KMT2A, OBD, PK, DLT, TKD, Cancer, Diabetes, ORR, Clinical study design, Safety, Patient, Cohort, HSCT, SETBP1, CR, DSM-IV codes, NUP214, DOR, Dicarboxylic acid, CRi, ASH, CD135, QT interval, RFS, FLT3, Arm, Cellular, FMS, Transplant, ALL, Toxic leukoencephalopathy, Gene family, Survival, Postcholecystectomy syndrome, DS, Trial of the century, Incidence, CRC, Infrared spectroscopy correlation table, AL, Osteopathic medicine in Canada, MN1, BID, CNS, KRAS, ATD, NUP98, Society, WBC, Pharmacokinetics, CLL, Acute leukemia, Common, ITD, Toxicity, AML, Cardiovascular disease, Pharmaceutical industry, Dentistry, Vaccine, Decitabine, DLBCL

Both BMF-219 and BMF-500 were originated in-house with Biomea’s proprietary FUSION™ system platform, which discovers and designs next-generation covalent-binding small molecule product candidates.

Key Points: 
  • Both BMF-219 and BMF-500 were originated in-house with Biomea’s proprietary FUSION™ system platform, which discovers and designs next-generation covalent-binding small molecule product candidates.
  • Methods: Doses of BMF-219 are escalated independently for each indication, initially in single-subject cohorts followed by a “3 + 3” design.
  • A subsequent amendment introduced quotas for KMT2Ar (MLL1r), NPM1 and other known menin-dependent mutations: CEBP/A, MLL1-PTD, MN1, NUP98, NUP214, PICALM-AF10, SETBP1.
  • The study was initiated in July 2023 and will enroll ~110 participants at approximately 30 sites.

Biomea Fusion Reports Third Quarter 2023 Financial Results and Corporate Highlights

Retrieved on: 
Monday, October 30, 2023
Week, DLBCL, FDA, Research, Research and development, NSCLC, Trial of the century, IND, DSM-IV codes, Food, Diabetes, Health Canada, G&A, BID, CRS, KRAS, Investment, R, NUP98, Glycated hemoglobin, CLL, CD135, Disease, Clinical trial, CRC, Cancer, QT interval, Menin, MM, FLT3, Safety, PDAC, Patient, FMS, Administration, AML, Mutation, Pharmaceutical industry, Medical imaging, Cryptocurrency, Osteopathic medicine in Canada

Both studies are now open for enrollment more than a quarter ahead of schedule.

Key Points: 
  • Both studies are now open for enrollment more than a quarter ahead of schedule.
  • Finally in this quarter, we also initiated the clinical study of our second, Biomea-discovered investigational covalent inhibitor, BMF-500, a novel FLT3 inhibitor.
  • Continued to advance development candidates derived from Biomea’s proprietary FUSION™ System platform to discover novel covalently binding small molecules.
  • G&A expenses were $17.1 million for the nine months ended September 30, 2023 compared to $15.2 million for the same period in 2022.

ORYZON Reports Financial Results and Corporate Updates for Quarter Ended September 30, 2023

Retrieved on: 
Friday, October 27, 2023
Research, ORY, Fruit, DMC, Food, Deficit spending, Risk, Medicine, ECNP, Schizophrenia, Platinum, ICMJE recommendations, SCLC, Charcot–Marie–Tooth disease, Sciatic nerve, Psychotherapy, Paclitaxel, NET, FCCC, MRD, Safety, EVOLUTION, BPD, Kabuki syndrome, Patient, Borderline personality disorder, ALS, Fox Chase Cancer Center, Genomics, Human, Duration, Glomus tumor, Measure (mathematics), Clinical trial, Dor, DSM-IV codes, Animal, European College of Neuropsychopharmacology, LSD1, FMS, CMT, FDA, IND, Innovation, ISIN, CNS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, R, HOPE, AML, Failure, Medical device, Pharmaceutical industry, Nursing, Cryptocurrency, EU, Science

Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the third quarter.

Key Points: 
  • Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the third quarter.
  • The company has started a structured dialogue with corporate pharma to identify a suitable partner to move forward the asset to Phase III, pending positive results.
  • General and administrative expenses were $0.7 and $2.9 million for the quarter and nine months ended September 30, 2023, respectively, compared to $0.7 and $3.3 million for the quarter and nine months ended September 30, 2022.
  • Net losses were $0.8 and $3.4 million for the quarter and nine months ended September 30, 2023, respectively, compared to $0.7 and $3.9 million for the quarter and nine months ended September 30, 2022.

AWS Announces Amazon EC2 Capacity Blocks for ML Workloads

Retrieved on: 
Tuesday, October 31, 2023
Software, Carriers and Services, Mobile, Wireless, Networks, Internet, Data Management, Technology, Artificial Intelligence, Security, Online Privacy, Other Technology, Telecommunications, Cloud, Leonardo, Amazon (company), H100, Life, Command-line interface, HPC, Synthetic media, Organization, LLM, NVIDIA GPU, Customer data platform, AMZN, Engineering, EFA, Growth, NVIDIA, SDK, Machine learning, GPU, Amazon Elastic Compute Cloud, Annapurna Labs, Computer graphics, Computer and network surveillance, AWS, FMS, ML, EC2, AI, Graphics processing unit, Deep learning, Automation, Computing, Cryptocurrency, Video game, Canva, Amazon

Amazon Web Services, Inc. (AWS), an Amazon.com company (NASDAQ: AMZN), today announced the general availability of Amazon Elastic Compute Cloud (EC2) Capacity Blocks for ML, an industry-first consumption model that enables any customer to access highly sought-after GPU compute capacity to run their short duration machine learning (ML) workloads.

Key Points: 
  • Amazon Web Services, Inc. (AWS), an Amazon.com company (NASDAQ: AMZN), today announced the general availability of Amazon Elastic Compute Cloud (EC2) Capacity Blocks for ML, an industry-first consumption model that enables any customer to access highly sought-after GPU compute capacity to run their short duration machine learning (ML) workloads.
  • With EC2 Capacity Blocks, customers can reserve hundreds of NVIDIA GPUs colocated in Amazon EC2 UltraClusters designed for high-performance ML workloads.
  • EC2 Capacity Blocks help ensure customers have reliable, predictable, and uninterrupted access to the GPU compute capacity required for their critical ML projects.
  • With EC2 Capacity Blocks, customers can reserve the amount of GPU capacity they need for short durations to run their ML workloads, eliminating the need to hold onto GPU capacity when not in use.

Fresenius Medical Care appoints Craig Cordola as new Management Board member for Care Delivery

Retrieved on: 
Tuesday, October 31, 2023
Kidney, Knowledge, Frankfurt Stock Exchange, FME, American College, Health administration, Financial Oversight and Management Board for Puerto Rico v. Aurelius Investment, LLC, Organization, Cyprus Securities and Exchange Commission, University of Houston–Clear Lake, Health, MBA, Lanny Cordola, Dialysis, Ascension, Supervisory board, Memorial Hermann Health System, COVID-19, Business administration, Retirement, Fresenius Medical Care, University of Texas at Austin, University, MHA, Master of Business Administration, Patient, FMS, Pharmaceutical industry, Nursing, Psychology

WALTHAM, Mass., Oct. 31, 2023 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, has appointed Craig Cordola (52) as new Management Board member for the globally operating Care Delivery segment.

Key Points: 
  • WALTHAM, Mass., Oct. 31, 2023 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, has appointed Craig Cordola (52) as new Management Board member for the globally operating Care Delivery segment.
  • Michael Sen, Chairman of the Supervisory Board of Fresenius Medical Care Management AG, said: "We are delighted to have Craig Cordola join the Management Board of Fresenius Medical Care as the leader of the global Care Delivery organization.
  • With this expertise, he will be a crucial player in the Management Board in implementing Fresenius Medical Care's turnaround and focusing on patient care."
  • Craig Cordola said: "I am excited to join Fresenius Medical Care, the global leader in kidney care and leading healthcare brand across this industry.

Fresenius Medical Care Demonstrates Commitment to Innovating Dialysis and Kidney Disease Care with Presentations at the American Society of Nephrology (ASN) Kidney Week 2023

Retrieved on: 
Tuesday, October 31, 2023
Kidney, Frankfurt Stock Exchange, Patient, Hemofiltration, Research, FME, Intelligence, III, HDF, Assessment of kidney function, AVF, Big data, Fatigue, HD, American Society of Nephrology, Saskatchewan River Sturgeon Management Board, Arteriovenous fistula, FX, Health, Society, Artificial intelligence, Dialysis, PO4, PSM, COVID-19, ASN, Machine learning, Congress, Fresenius Medical Care, FKC, RBV, Creatinine, Scientific Committee on Oceanic Research, FMS, Peritoneum, IDS, Data science, Pharmaceutical industry, Medical device, Hemodialysis, Nephrology

Fresenius Medical Care announces presentations at the American Society of Nephrology (ASN) Kidney Week 2023.

Key Points: 
  • Fresenius Medical Care announces presentations at the American Society of Nephrology (ASN) Kidney Week 2023.
  • Scientific and medical experts from across Fresenius Medical Care will present research related to many important topics in kidney disease care.
  • Through its network of 4,050 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approximately 344,000 patients around the globe.
  • Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius Medical Care Achieves Key AI Milestone With First-Phase Completion of Largest Global Dialysis Clinical Dataset

Retrieved on: 
Thursday, October 26, 2023
Cloud, Kidney, Knowledge, Frankfurt Stock Exchange, Global Medical Device Nomenclature, FME, Innovation, HIPAA, Physician, MD, Saskatchewan River Sturgeon Management Board, Doctor of Philosophy, Health, Research, Society, Artificial intelligence, Quality of life, Digital technology, Dialysis, Database, COVID-19, Medicine, Fresenius Medical Care, Kidney disease, Privacy, AI, Patient, FMS, GDPR, Medical imaging, Medical device, Pharmaceutical industry

"The data created across Fresenius Medical Care's global clinical footprint is unmatched in its breadth and depth, and is one of the company's greatest competitive advantages," said Stuart McGuigan, Global Chief Information Officer of Fresenius Medical Care.

Key Points: 
  • "The data created across Fresenius Medical Care's global clinical footprint is unmatched in its breadth and depth, and is one of the company's greatest competitive advantages," said Stuart McGuigan, Global Chief Information Officer of Fresenius Medical Care.
  • Through its network of 4,050 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approximately 344,000 patients around the globe.
  • Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers.
  • Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

Seoul Defense Dialogue 2023 and the Critical Role of the 'International Defense Briefing' in Shaping Tomorrow's Defense Decisions

Retrieved on: 
Thursday, October 19, 2023
Korean War, Intelligence, Prosperity, Foreign, Heart, Dialogue, Solidarity, Multilateralism, Foreign internal defense, FMS, Arms industry, Risk management

At the heart of these discussions lies the need for timely, accurate, and comprehensive information on defense-related matters, precisely what the " International Defense Briefing " provides.

Key Points: 
  • At the heart of these discussions lies the need for timely, accurate, and comprehensive information on defense-related matters, precisely what the " International Defense Briefing " provides.
  • It is one of the key topics of discussion at the Seoul Defense Dialogue 2023, and the "International Defense Briefing" has a dedicated special session addressing this very issue.
  • The "International Defense Briefing" offers expert insights into this transformative technology and its potential impact on the global defense landscape.
  • Don't miss out on this invaluable tool – subscribe to the "International Defense Briefing" today and stay ahead in the world of international defense.

IBM Expands Relationship with AWS to Bring Generative AI Solutions and Dedicated Expertise to Clients

Retrieved on: 
Wednesday, October 18, 2023
Cloud, Knowledge, NYSE, IBM Consulting, History, Bouygues Telecom, Human, News, Organization, Amazon Web Services, Generative, Associated Global Systems, Partnership, SES Platform Services, Growth, Ecosystem, Amazon SageMaker, API, FMS, Consultant, AWS, AI, IBM, Automation, Software as a service, Sales, Online shopping, Software

ARMONK, N.Y., Oct. 18, 2023 /PRNewswire/ -- IBM (NYSE: IBM) today announced an expansion of its relationship with Amazon Web Services (AWS) to help more mutual clients operationalize and derive value from generative artificial intelligence (AI). As part of this, IBM Consulting aims to deepen and expand its generative AI expertise on AWS by training 10,000 consultants by the end of 2024; the two organizations also plan to deliver joint solutions and services upgraded with generative AI capabilities designed to help clients across critical use cases.

Key Points: 
  • IBM Consulting and AWS already serve clients across a variety of industries with a range of AI solutions and services.
  • Now, the companies are enhancing those solutions and services with the power of generative AI designed to help clients integrate AI quickly into business and IT operations building on AWS.
  • Additionally, for clients looking to modernize on AWS, IBM Consulting plans to integrate AWS generative AI services into its proprietary IBM Consulting Cloud Accelerator to help accelerate the cloud transformation process.
  • AI expertise and a deep understanding of AWS capabilities are critical for clients looking to implement generative AI, and IBM is already providing mutual clients with access to professionals from IBM Consulting's Center of Excellence for Generative AI with specialized generative AI expertise.